Abstract
Background. Test, trace and isolate are the three crucial components of the response to COVID-19 identified by the World Health Organisation. Mathematical models of contact tracing often over-simplify the ability of traced contacts to quarantine or isolate. Method. We use an age-structured branching process model of individual disease transmission combined with a detailed model of symptom onset, testing, contact quarantine and case isolation to model each aspect of the test, trace, isolate strategy. We estimated the effective reproduction number under a range of scenarios to understand the importance of each aspect of the system. Findings. People's ability to quarantine and isolate effectively is a crucial component of a successful contact tracing system. 80% of cases need to be quarantined or isolated within 4 days of quarantine or isolation of index case to be confident the contact tracing system is effective. Interpretation. Provision of universal support systems to enable people to quarantine and isolate effectively, coupled with investment in trained public health professionals to undertake contact tracing, are crucial to success. We predict that a high-quality, rapid contact tracing system with strong support structures in place, combined with moderate social distancing measures, is required to contain the spread of COVID-19. Funding. This work was funded by the Ministry of Business, Innovation and Employment, New Zealand and Te Punaha Matatini, the NZ Centre of Research Excellence for Complex Systems.
Competing Interest Statement
This paper was written in Dr Verrall's capacity as Senior Lecturer at the University of Otago, not in her capacity as a candidate for Parliament. The views in this paper are not necessarily the views of the New Zealand Labour Party. All other authors have no competing interests.
Funding Statement
This work was funded by Te Punaha Matatini, the New Zealand Centre of Research Excellence for Complex Syatems
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee Ministry of Health, New Zealand.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated to reflect a change in the authors competing interests.
Data Availability
Data is available trough the New Zealand Ministry of Health. It cannot be made publicly available due to confidentiality concerns.
